Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07165132 · ClinicalTrials.gov registry record · Phase 1

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

A Phase 1 study, sponsored by RayzeBio.

Recruiting
Registry status
Phase 1
Development phase
104
Enrollment target

NCT07165132: Recruiting Phase 1 study, sponsored by RayzeBio.

NCT07165132 is a Phase 1 study that is actively recruiting participants, run by RayzeBio. The registered enrollment target is 104 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07165132, a Phase 1 study, is actively recruiting participants, sponsored by RayzeBio.

RECRUITING
Registry status
Phase 1
Development phase
104 participants
Enrollment target

Study Summary

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

Primary Outcome

Incidence of DLTs during RYZ 401 Treatment

Interventions

  • DRUG RYZ401

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2025-12-03
Est. Completion 2033-04
Phase Phase 1
RayzeBio

5 total trials

What NCT07165132 shows while recruiting

NCT07165132 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% higher).

The record links to 0 conditions, and to 1 intervention - of which RYZ401 is the first listed.

NCT07165132 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07165132 about?

NCT07165132 is a clinical study titled "Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.". The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

What is the current status of trial NCT07165132?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2025-12-03. Estimated completion is 2033-04.

What interventions are being tested in trial NCT07165132?

The interventions under investigation include: RYZ401 (DRUG).

Who is sponsoring clinical trial NCT07165132?

This trial is sponsored by RayzeBio, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07165132's enrollment target sits among peer trials

104 536th of 2000 higher than 1,460 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07165132, the US trial registry maintained by the National Library of Medicine. NCT07165132 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.